glp-1 and migraines Medications, according to a Neurologist. 🧠👩🏼‍⚕️💖, ⚠️ Disclaimer: This content is for educational and informational purposes only. It is not intended as medical advice. , #migraine GLP-1 drugs show promise for

triple agonists suppress appetite and actively increase energy expenditure

After 24 months of follow-up, 68.2% of individuals less than 65 years old had discontinued GLP-1RAs, with the proportion rising to 75.3% for those 6574 years old and 82.6% for those 75 or older (116)

[1] [2] These results should be interpreted in context: they reflect specific dose groups within obesity cohorts and may not apply across all doses, populations, or indications such as type 2 diabetes

If you are curious where it fits in your plan, that is a great consultation question

To prevent this, the Centers for Medicare and Medicaid Services (CMS) could require state Medicaid programs to meet standardized prior authorization criteria before getting access to lower prices